1. Service Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for
Study
1.2.3. Key Market
Segmentations
2. Research Methodology
2.1. Objective of the
Study
2.2. Baseline Methodology
2.3. Key Industry
Partners
2.4. Major Association
and Secondary Sources
2.5. Forecasting
Methodology
2.6. Data Triangulation
& Validation
2.7. Assumptions and
Limitations
3. Executive Summary
3.1. Overview of the
Market
3.2. Overview of Key
Market Segmentations
3.3. Overview of Key
Market Players
3.4. Overview of Key
Regions/Countries
3.5. Overview of Market
Drivers, Challenges, and Trends
4. Voice of Customer
5.
Global Prostate Cancer Therapeutics Market Outlook
5.1. Market Size &
Forecast
5.1.1. By Value
5.2. Market Share &
Forecast
5.2.1. By Treatment (Hormonal
Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
5.2.1.1.
Hormonal Therapy
5.2.1.1.1.
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
5.2.1.1.2.
Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
5.2.1.1.3.
Anti-Androgen
5.2.1.2.
Chemotherapy
5.2.1.2.1.
Taxotere
5.2.1.2.2.
Jevtana
5.2.1.3.
Immunotherapy
5.2.1.3.1.
Provenge
5.2.1.4.
Target Therapy
5.2.1.4.1.
Xofigo
5.2.1.5.
Others
5.2.2. By End User (Hospitals,
Oncology Clinics, Ambulatory Surgical Centers, Others)
5.2.3. By Region
5.2.4. By Company (2022)
5.3. Market Map
5.3.1. By Treatment
5.3.2. By End User
6.
North America Prostate Cancer Therapeutics Market Outlook
6.1. Market Size &
Forecast
6.1.1. By Value
6.2. Market Share &
Forecast
6.2.1. By Treatment (Hormonal
Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
6.2.1.1.
Hormonal Therapy
6.2.1.1.1.
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
6.2.1.1.2.
Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
6.2.1.1.3.
Anti-Androgen
6.2.1.2.
Chemotherapy
6.2.1.2.1.
Taxotere
6.2.1.2.2.
Jevtana
6.2.1.3.
Immunotherapy
6.2.1.3.1.
Provenge
6.2.1.4.
Target Therapy
6.2.1.4.1.
Xofigo
6.2.1.5.
Others
6.2.2. By End User (Hospitals,
Oncology Clinics, Ambulatory Surgical Centers, Others)
6.2.3. By Country
6.3. North America:
Country Analysis
6.3.1. United States Prostate
Cancer Therapeutics Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Treatment
6.3.1.2.2.
By End
User
6.3.2. Canada Prostate
Cancer Therapeutics Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Treatment
6.3.2.2.2.
By End
User
6.3.3. Mexico Prostate
Cancer Therapeutics Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Treatment
6.3.3.2.2.
By End User
7.
Europe Prostate Cancer Therapeutics Market Outlook
7.1. Market Size &
Forecast
7.1.1. By Value
7.2. Market Share &
Forecast
7.2.1. By Treatment (Hormonal
Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
7.2.1.1.
Hormonal Therapy
7.2.1.1.1.
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
7.2.1.1.2.
Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
7.2.1.1.3.
Anti-Androgen
7.2.1.2.
Chemotherapy
7.2.1.2.1.
Taxotere
7.2.1.2.2.
Jevtana
7.2.1.3.
Immunotherapy
7.2.1.3.1.
Provenge
7.2.1.4.
Target Therapy
7.2.1.4.1.
Xofigo
7.2.1.5.
Others
7.2.2. By End User (Hospitals,
Oncology Clinics, Ambulatory Surgical Centers, Others)
7.2.3. By Country
7.3. Europe: Country
Analysis
7.3.1. France Prostate
Cancer Therapeutics Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Treatment
7.3.1.2.2.
By End
User
7.3.2. Germany Prostate
Cancer Therapeutics Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Treatment
7.3.2.2.2.
By End
User
7.3.3. United Kingdom Prostate
Cancer Therapeutics Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Treatment
7.3.3.2.2.
By End
User
7.3.4. Italy Prostate
Cancer Therapeutics Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Treatment
7.3.4.2.2.
By End
User
7.3.5. Spain Prostate
Cancer Therapeutics Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Treatment
7.3.5.2.2.
By End
User
8.
Asia-Pacific Prostate Cancer Therapeutics Market Outlook
8.1. Market Size &
Forecast
8.1.1. By Value
8.2. Market Share &
Forecast
8.2.1. By Treatment (Hormonal
Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
8.2.1.1.
Hormonal Therapy
8.2.1.1.1.
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
8.2.1.1.2.
Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
8.2.1.1.3.
Anti-Androgen
8.2.1.2.
Chemotherapy
8.2.1.2.1.
Taxotere
8.2.1.2.2.
Jevtana
8.2.1.3.
Immunotherapy
8.2.1.3.1.
Provenge
8.2.1.4.
Target Therapy
8.2.1.4.1.
Xofigo
8.2.1.5.
Others
8.2.2. By End User (Hospitals,
Oncology Clinics, Ambulatory Surgical Centers, Others)
8.2.3. By Country
8.3. Asia-Pacific:
Country Analysis
8.3.1. China Prostate
Cancer Therapeutics Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Treatment
8.3.1.2.2.
By End
User
8.3.2. Japan Prostate
Cancer Therapeutics Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Treatment
8.3.2.2.2.
By End
User
8.3.3. India Prostate
Cancer Therapeutics Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Treatment
8.3.3.2.2.
By End
User
8.3.4. South Korea Prostate
Cancer Therapeutics Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Treatment
8.3.4.2.2.
By End
User
8.3.5. Australia Prostate
Cancer Therapeutics Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Treatment
8.3.5.2.2.
By End
User
9.
South America Prostate Cancer Therapeutics Market Outlook
9.1. Market Size &
Forecast
9.1.1. By Value
9.2. Market Share &
Forecast
9.2.1. By Treatment (Hormonal
Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
9.2.1.1.
Hormonal Therapy
9.2.1.1.1.
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
9.2.1.1.2.
Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
9.2.1.1.3.
Anti-Androgen
9.2.1.2.
Chemotherapy
9.2.1.2.1.
Taxotere
9.2.1.2.2.
Jevtana
9.2.1.3.
Immunotherapy
9.2.1.3.1.
Provenge
9.2.1.4.
Target Therapy
9.2.1.4.1.
Xofigo
9.2.1.5.
Others
9.2.2. By End User (Hospitals,
Oncology Clinics, Ambulatory Surgical Centers, Others)
9.2.3. By Country
9.3. South America:
Country Analysis
9.3.1. Brazil Prostate
Cancer Therapeutics Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Treatment
9.3.1.2.2.
By End
User
9.3.2. Argentina Prostate
Cancer Therapeutics Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Treatment
9.3.2.2.2.
By End
User
9.3.3. Colombia Prostate
Cancer Therapeutics Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Treatment
9.3.3.2.2.
By End
User
10.
Middle East and Africa Prostate Cancer Therapeutics
Market Outlook
10.1.
Market Size & Forecast
10.1.1. By Value
10.2.
Market Share & Forecast
10.2.1. By Treatment (Hormonal
Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
10.2.1.1. Hormonal Therapy
10.2.1.1.1.
Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
10.2.1.1.2.
Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
10.2.1.1.3.
Anti-Androgen
10.2.1.2. Chemotherapy
10.2.1.2.1.
Taxotere
10.2.1.2.2.
Jevtana
10.2.1.3. Immunotherapy
10.2.1.3.1.
Provenge
10.2.1.4. Target Therapy
10.2.1.4.1.
Xofigo
10.2.1.5. Others
10.2.2. By End User (Hospitals,
Oncology Clinics, Ambulatory Surgical Centers, Others)
10.2.3. By Country
10.3.
MEA: Country Analysis
10.3.1. UAE Prostate Cancer
Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1.
By Treatment
10.3.1.2.2.
By End
User
10.3.2. Saudi Arabia Prostate
Cancer Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1.
By Treatment
10.3.2.2.2.
By End
User
10.3.3. Saudi Africa Prostate
Cancer Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1.
By Treatment
10.3.3.2.2.
By End
User
10.3.4. Turkey Prostate
Cancer Therapeutics Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1.
By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1.
By Treatment
10.3.4.2.2.
By End
User
10.3.5. Egypt Prostate
Cancer Therapeutics Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1.
By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1.
By Treatment
10.3.5.2.2.
By End
User
11. Market Dynamics
11.1.
Drivers
11.1.1. Increasing
Prevalence of Prostate Cancer.
11.1.2. Adoption of Novel
Screening and Diagnostic Technologies
11.1.3. Surge in Research
and Development
11.2.
Challenges
11.2.1.
High Cost of Cancer Treatment
11.2.2. Side Effects of Hormonal
Treatment
12. Market Trends &
Developments
12.1. Product Launches
12.2. Mergers &
Acquisitions
12.3. Technological
Advancements
13. Clinical Trial
Analysis
14. Global Prostate
Cancer Therapeutics Market: SWOT Analysis
15. Competitive
Landscape
15.1. Business Overview
15.2. Product Offerings
15.3. Recent Developments
15.4. Financials (In Case
of Listed Companies)
15.5. Key Personnel
15.6. SWOT Analysis
15.6.1. Johnson &
Johnson Services, Inc.
15.6.2. Astellas Pharma Inc.
15.6.3. Eli Lilly and
Company
15.6.4. Sanofi S.A.
15.6.5. Ipsen Pharma
15.6.6. Bayer AG
15.6.7. AstraZeneca Plc
15.6.8. Valeant
Pharmaceuticals International, Inc.
15.6.9. Merck & Co.,
Inc.
15.6.10. Pfizer Inc.
16. Strategic Recommendations